[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. (AMRX) Form 4 shows that reporting person Shah Nikita, listed as Executive Vice President and filing as an officer, sold 50,000 shares of Class A common stock on 08/12/2025. The filing reports a weighted average price of $9.04 and discloses the sales occurred in multiple transactions at prices ranging from $9.03 to $9.07. The sale is reported as a direct disposition.

The filing states the reporting person now beneficially owns 338,929 shares directly. The Form 4 was signed by attorney-in-fact Denis Butkovic on 08/13/2025. No derivative securities are reported on this Form 4.

Positive

• Full disclosure of transaction details including date, number of shares, weighted average price, and price range
• Reporting person retains 338,929 shares of Class A common stock as direct beneficial ownership

Negative

• Reported sale of 50,000 Class A common shares on 08/12/2025
• Sale executed at a weighted average price of $9.04, reducing direct holdings

Insights

Financial Analyst

TL;DR: Executive sale of 50,000 AMRX shares at ~$9.04; reporting shows continued direct ownership of 338,929 shares.

The transaction is clearly disclosed with a weighted average price of $9.04 and a stated price range of $9.03–$9.07, which aids transparency. The sale was executed on 08/12/2025 and reported on Form 4, with no derivative positions listed. From an analytic standpoint, the filing documents a material insider sale in absolute terms but also shows substantial retained direct ownership. Without additional company- or market-level context, the event is a factual disclosure rather than a clear signal about company fundamentals.

Corporate Governance Expert

TL;DR: Routine Form 4 filing documents an officer's direct sale and continued beneficial ownership; disclosure includes transaction price details.

The filing meets disclosure standards by providing the transaction date, number of shares sold, weighted average price, and an explanatory footnote on the price range. The signature by an attorney-in-fact on 08/13/2025 is included. The report does not indicate any derivatives or 10b5-1 plan designation on its face. As filed, it is a transparent insider disposition; governance implications depend on broader patterns of insider trading and context not present in this document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Nikita

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BLVD.

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/12/2025		S		50,000	D	$9.04(1)	338,929	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.07 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Amneal Pharmaceuticals (AMRX)?

The Form 4 was filed for Shah Nikita, listed as Executive Vice President and an officer of Amneal Pharmaceuticals, Inc.

How many AMRX shares were sold and when?

50,000 shares of Class A common stock were sold on 08/12/2025.

At what price were the AMRX shares sold?

The filing reports a weighted average price of $9.04, with sales occurring at prices ranging from $9.03 to $9.07.

How many AMRX shares does the reporting person own after the sale?

Following the reported transaction, the reporting person beneficially owns 338,929 shares (direct ownership).

When was the Form 4 signed?

The Form 4 bears the signature of attorney-in-fact Denis Butkovic dated 08/13/2025.